.svg){kind=small}
Jun-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Market Insights Snapshot
In June 2026, Indiva concentrated entirely in Capsules with a 100.0% category share, while brand sales declined 62.37% year over year and 24.89% month over month within Capsules; alongside this volume contraction, the average price rose 34.65% year over year to $32.27, indicating mix or pack-size effects. With no revenue contribution from other categories and a single-category exposure, the combination of a 24.89% MoM drop and a 62.37% YoY drop implies demand elasticity is biting harder than price can offset, and the pattern suggests Indiva is leaning on price per unit rather than breadth, which elevates near-term volatility risk for June 2026.
Indiva’s narrow focus positions the brand as a Capsules specialist, but the 62.37% YoY and 24.89% MoM declines paired with a 34.65% YoY price increase indicate that higher realized price is not translating to share defense, and a single-category mix magnifies the impact of any shelf or patient-flow shifts. Given a rank of 3 in Capsules in British Columbia, holding a top-three slot while volumes contract by double digits suggests Indiva’s positioning relies on premiumized pricing and retention in a shrinking demand pocket, implying the brand may need either assortment diversification or pack architecture changes to stabilize its base.
Competitive Landscape
Indiva sits at #6 in ON Capsules in June 2026, unchanged YoY from #6, with a 0-rank move over the past three months and a one-spot gap from its peak at #5 in April 2025; meanwhile, Glacial Gold climbed from #4 to #2 (+2 ranks) as its sales grew 45.7% YoY, and Redecan slipped from #2 to #3 (-1 rank) with a 41.2% YoY sales decline. Against a leader board where Aspire held #1 for a second year (0-rank change) and Emprise Canada maintained #5 (0-rank change) with 23.6% YoY sales growth, Indiva’s stationary #6 alongside a prior peak at #5 implies a stable but squeezed position where modest share gains likely require displacing a flat competitor rather than riding category growth.
Notable Products
CBG/THC 1:2 Blips Tablets 20-Pack (100mg CBG, 200mg THC) posted the steepest decline in June 2026 at -78.99% MoM, while Big Blips THC Tablets 55-Pack (550mg) fell -21.59% MoM and held rank 1. Blips THC Tablets 25-Pack (250mg) dropped -26.03% MoM at rank 2, and three of the top four SKUs are Capsules, concentrating mix away from Edibles. With rank 1 and rank 2 both declining over -20% MoM and Capsules representing 100% of the ranked lineup, the pattern implies Indiva is over-weighted to a shrinking Capsules core and may need diversification despite Big Blips generating $79,935 in June 2026.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
